Author:
Ma Wai-Kit,Chiu Peter Ka-Fung
Reference51 articles.
1. Abdi H, Zargar H, Goldenberg SL, et al. Multiparametric magnetic resonance imaging-targeted biopsy for the detection of prostate cancer in patients with prior negative biopsy results. Urol Oncol. 2015;33(4):165.e1–7.
2. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–22.
3. American Urological Association (AUA) and Society of Abdominal Radiology (SAR) Joint Consensus Statement. Prostate MRI and MRI-targeted biopsy in patients with prior negative biopsy. Collaborative initiative of the American Urological Association and the Society of Abdominal Radiology’s Prostate Cancer Disease-Focused Panel. 2016.
https://c.ymcdn.com/sites/abdominalradiology.site-ym.com/resource/resmgr/Edu_DFPprostate/AUA-SAR.pdf
.
4. Arsov C, Rabenalt R, Blondin D, et al. Prospective randomized trial comparing magnetic resonance imaging (MRI)guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies. Eur Urol. 2015;68(4):713–20.
5. Baco E, Rud E, Eri LM, et al. A randomized controlled trial to assess and compare the outcomes of two-core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12-core systematic biopsy. Eur Urol. 2016;69:149–56.